Related Experiment Video
Updated: Aug 14, 2026
Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
Published on: August 8, 2012
Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element
1Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
The overexpression of HER-2/neu proto-oncogene has been found in a variety of human cancers. In particular, the amplification and overexpression of HER-2/neu gene were found in 20-30% of breast and ovarian cancer patients with a decreased survival and an increased relapse rates. To target the breast cancer cells overexpressing HER-2/neu mRNA, a novel approach is described that combines the antisense principle and the biochemical property of a translation regulator, an iron responsive element (IRE). This report shows that a HER-2/neu antisense IRE-reporter gene can be preferentially expressed in the breast cancer cells that overexpress HER-2/neu mRNA. This antisense IRE-mediated gene expression system may be applied broadly to target other cell type that uniquely expresses or overexpresses a known gene.
Insights
A novel antisense IRE-reporter gene system targets breast cancer cells overexpressing HER2/neu mRNA. This approach shows preferential expression in cancer cells, offering a new strategy for targeted cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- HER-2/neu proto-oncogene overexpression is linked to poor prognosis in breast and ovarian cancers.
- Targeting HER-2/neu offers a potential therapeutic strategy for these malignancies.
- Current therapies face challenges in selectively targeting cancer cells.
Purpose of the Study:
- To develop a novel gene expression system targeting breast cancer cells overexpressing HER-2/neu mRNA.
- To investigate the preferential expression of a HER-2/neu antisense IRE-reporter gene in cancer cells.
- To establish a new platform for targeted gene therapy in cancer.
Main Methods:
- Construction of a HER-2/neu antisense IRE-reporter gene.
- Utilizing the antisense principle combined with an iron-responsive element (IRE).
- Assessing the preferential expression of the reporter gene in HER-2/neu overexpressing breast cancer cells.
Main Results:
- The HER-2/neu antisense IRE-reporter gene demonstrated preferential expression in breast cancer cells with high HER-2/neu mRNA levels.
- The study successfully validated the concept of IRE-mediated gene expression for targeted therapy.
- The system showed potential for selective targeting of cancer cells based on specific gene expression.
Conclusions:
- The developed antisense IRE-mediated gene expression system is effective in targeting HER-2/neu overexpressing breast cancer cells.
- This novel approach holds promise for developing targeted cancer therapies.
- The system's broad applicability suggests potential for targeting other cancers with unique gene expression profiles.
